Difference between revisions of "Proligestone"

From Dog
 
Line 3: Line 3:
 
Proligestone induces suppression of the hypothalamic-pituitary-adrenal axis, resulting in suppression of corticotrophin-releasing hormone and plasma glucocorticoid levels<ref>Selman PJ ''et al'' (1996) Binding specificity of medroxyprogesterone acetate and proligestone for the progesterone and glucocorticoid receptor in the dog. ''Steroids'' '''61(3)''':133-137</ref>, reduced insulin sensitivity and a predisposition to [[diabetes mellitus]], mammary hyperplasia and [[acromegaly]]<ref>Selman PJ ''et al'' (1997) Effects of progestin administration on the hypothalamic-pituitary-adrenal axis and glucose homeostasis in dogs. ''J Reprod Fertil Suppl'' '''51''':345-354</ref>.
 
Proligestone induces suppression of the hypothalamic-pituitary-adrenal axis, resulting in suppression of corticotrophin-releasing hormone and plasma glucocorticoid levels<ref>Selman PJ ''et al'' (1996) Binding specificity of medroxyprogesterone acetate and proligestone for the progesterone and glucocorticoid receptor in the dog. ''Steroids'' '''61(3)''':133-137</ref>, reduced insulin sensitivity and a predisposition to [[diabetes mellitus]], mammary hyperplasia and [[acromegaly]]<ref>Selman PJ ''et al'' (1997) Effects of progestin administration on the hypothalamic-pituitary-adrenal axis and glucose homeostasis in dogs. ''J Reprod Fertil Suppl'' '''51''':345-354</ref>.
  
This drug is used for estrus suppression, [[pseudopregnancy]] and treatment of pituitary [[dwarfism]]<ref>Knottenbelt CM & Herrtage ME (2002) Use of proligestone in the management of three German shepherd dogs with pituitary dwarfism. ''J Small Anim Pract'' '''43(4)''':164-170</ref>.
+
This drug is used for estrus suppression, [[aggression]], [[pseudopregnancy]] and treatment of pituitary [[dwarfism]]<ref>Knottenbelt CM & Herrtage ME (2002) Use of proligestone in the management of three German shepherd dogs with pituitary dwarfism. ''J Small Anim Pract'' '''43(4)''':164-170</ref>.
  
 
Side-effects include steroid-induced hepatopathy, chronic [[pyelonephritis]], aspecific [[dermatitis]] and mucinous dysplasia of the gall bladder<ref>Selman PJ ''et al'' (1995) Comparison of the histological changes in the dog after treatment with the progestins medroxyprogesterone acetate and proligestone. ''Vet Q'' '''17(4)''':128-133</ref>.
 
Side-effects include steroid-induced hepatopathy, chronic [[pyelonephritis]], aspecific [[dermatitis]] and mucinous dysplasia of the gall bladder<ref>Selman PJ ''et al'' (1995) Comparison of the histological changes in the dog after treatment with the progestins medroxyprogesterone acetate and proligestone. ''Vet Q'' '''17(4)''':128-133</ref>.

Latest revision as of 23:20, 24 March 2013

Proligestone is a synthetic steroidal progesterone drug (progestin).

Proligestone induces suppression of the hypothalamic-pituitary-adrenal axis, resulting in suppression of corticotrophin-releasing hormone and plasma glucocorticoid levels[1], reduced insulin sensitivity and a predisposition to diabetes mellitus, mammary hyperplasia and acromegaly[2].

This drug is used for estrus suppression, aggression, pseudopregnancy and treatment of pituitary dwarfism[3].

Side-effects include steroid-induced hepatopathy, chronic pyelonephritis, aspecific dermatitis and mucinous dysplasia of the gall bladder[4].

Recommended dose is 5 mg/kg.

References

  1. Selman PJ et al (1996) Binding specificity of medroxyprogesterone acetate and proligestone for the progesterone and glucocorticoid receptor in the dog. Steroids 61(3):133-137
  2. Selman PJ et al (1997) Effects of progestin administration on the hypothalamic-pituitary-adrenal axis and glucose homeostasis in dogs. J Reprod Fertil Suppl 51:345-354
  3. Knottenbelt CM & Herrtage ME (2002) Use of proligestone in the management of three German shepherd dogs with pituitary dwarfism. J Small Anim Pract 43(4):164-170
  4. Selman PJ et al (1995) Comparison of the histological changes in the dog after treatment with the progestins medroxyprogesterone acetate and proligestone. Vet Q 17(4):128-133